C ontrol of therapeutic gene expression in tumors is important for gene therapy. Using an inducible promoter to control therapeutic gene expression makes spatial and temporal targeting of therapy possible. 1 -3 This is critical for the use of potent, but cytotoxic, cytokines that are normally of limited practical utility due to systemic toxicity concerns. An example of a cytokine with potential therapeutic application is tumor necrosis factor (TNF )-, which exerts cytotoxic effects on a wide range of tumor cells by inducing apoptosis 4 and which also activates the immune system. 5 However, its clinical use in humans has been greatly limited by systemic toxicity. 6 In addition to minimizing side effects, if therapeutic gene expression can be induced by an exogenous stimulus such as radiation or heat shock, a combined therapeutic effect can be expected.
Hyperthermia is a promising approach for cancer therapy 7 and has often been used in multimodality strategies as it can enhance the tumor killing effect of chemotherapy, 8 radiotherapy, 9 and immunotherapy. 10 We have investigated hyperthermia produced by means of submicron magnetic particles. Magnetic particles generate heat under an alternating magnetic field ( AMF ) by hysteresis loss. 11 To promote adsorption and accumulation of magnetic particles in tumor cells, we developed magnetite cationic liposomes (MCLs). 12, 13 When the MCLs were administrated to tumor tissue by local injection and AMF was applied in an in vivo study, complete tumor regression was observed in 87.5% of the rats. 14 The gadd ( growth arrest and DNA damage ) 153 gene, a member of the gadd transcription factor family, was originally identified as a DNA damaging reagent in hamster cell lines. 15 -17 Ropp et al 18 reported that heat and oxidative stress could be related to this effect. We constructed a plasmid with the TNF -gene under the control of the gadd 153 promoter and demonstrated a combined therapeutic effect with heat stress in an in vitro study. 19 Moreover, we showed that the gadd 153 promoter was further activated by TNF -gene expression, causing an extremely high cytotoxic effect. 20 This means that the gadd 153-TNF -system is effective not only in killing tumor cells in heated regions of the tissue, but also in the surrounding areas.
In the present study, we have combined TNF -gene therapy driven by a heat -inducible promoter with hyperthermia produced by irradiation of MCLs. The MCLs and a plasmid containing the human TNF -gene under control of the gadd 153 promoter were injected into solid U251 -SP human tumors formed subcutaneously in nude mice, and AMF was applied. This novel strategy has two targeting functions. One is based on the magnetites, which are specifically heated under an AMF, and the other is based on the inducibility of the gadd 153 promoter. We investigated the feasibility of this strategy in vivo.
MATERIALS AND METHODS

Cell line and establishment of tumors in nude mice
U251 -SP human glioma cells were grown in minimum essential medium, supplemented with 10% fetal calf serum, 10 mM nonessential amino acids, 0.1 g /mL streptomycin sulfate, and 100 U /mL potassium penicillin G. The cells were incubated at 378C in a humidified atmosphere of 5% CO 2 and 95% air.
A total of 3Â10 7 U251 -SP cells were transplanted along the right flank of 4 -week -old female athymic mice ( Japan SLC, Hanamatsu, Japan ). Tumor-bearing mice were randomized for the studies when tumors reached 8Â8 mm in size. These mice were housed in a special pathogen-free animal facility.
Plasmid construction and transfection
The plasmid JymCAT0 including the gadd 153 promoter was kindly provided by Prof. Nikki Holbrook. 15 The plasmid SKhTNF encoding human TNF -gene was kindly provided by Dr. Hirohumi Hamada. In the plasmid pGadTNF, 19 the human TNF -gene is under the control of the gadd 153 promoter.
A total of 20 g of pGadTNF was introduced into 8Â8 mm tumors by the lipofection method, which uses N -( -trimethylammonioacetyl )-didodecyl -D -glutamate chloride ( Sogo Pharmaceutical, Tokyo, Japan ), dilauroylphosphatidylcholine, and dioleoylphosphatidylethanolamine (Sigma Chemical, St. Louis, MO ) in a 1:2:2 molar ratio as described previously. 19 
Preparation of MCLs and hyperthermia treatment
Magnetite (Fe 3 O 4 ; average particle size: 10 nm ), used as the core of the MCLs, was the kind gift of Toda Kogyo ( Hiroshima, Japan ). The MCLs were prepared with colloidal magnetite and a lipid mixture consisting of N -( -trimethylammonioacetyl )-didodecyl -D -glutamate chloride, dilauroylphosphatidylcholine, and dioleoylphosphatidylethanolamine in a 1:2:2 molar ratio as previously described. 12 All MCLs concentrations are expressed as the net magnetite concentration.
One day after pGadTNF transfection, 0.2 mL of MCLs solution ( net magnetite weight: 3 mg ) was injected at the center of the tumor using a 25-gauge needle and an infusion pump ( SP100i; World Precision Instruments, Sarasota, FL ) for 30 minutes. One day later, mice were subjected to hyperthermia treatment. A magnetic field was created by using a horizontal coil ( inner diameter: 7 cm; length: 7 cm ) with a transistor inverter (LTG -100 -05; Dai -ichi High Frequency, Tokyo, Japan ). 12 Anesthetized mice were laid inside the coil such that the tumor region was at the center. The magnetic field frequency and intensity were 118 kHz and 30.6 kA / m ( 384 Oe ), respectively. Tumor and rectal temperatures were measured by optical fiber probe ( FX -9020; Anritsu Meter, Tokyo, Japan ).
TNF -ELISA
For the TNF -ELISA, tumor samples were homogenized in ice -cold tris ( hydroxymethyl ) aminomethane buffer (pH 7.6 ) containing the protease inhibitor phenylmethylsulfonyl fluoride (1 mM ), leupeptin (1 g/mL), N -tosyl -L -phenylalanyl chloromethyl ketone (1 g/mL ), N -tosyl -L -lysyl chloromethyl ketone (1 g /mL ), and pepstatin ( 1 g/mL). The homogenates were centrifuged at 14,000 rpm at 48C for 10 minutes, 100 L of the supernatants was subjected to the human TNF -ELISA (Endogen, Woburn, MA ) in duplicate, and the ELISA was performed according to the manufacturer's instructions. The standards were calibrated using WHO reference lot 87/ 650. One picogram of standards was equivalent to one WHO picogram. The total protein content of the tumor homogenates was determined by using the DC protein assay reagent ( Bio -Rad Laboratories, Hercules, CA ).
To determine the human TNF -concentration in the serum of the mice, 50 L of serum was subjected to the ultra-sensitive TNF -ELISA ( Biosource International, Camarillo, CA ).
Determination of tumor volume
Tumor sizes were measured every 3 days. The volume was determined by the following formula:
where the unit of length and width is a millimeter.
Preparation of specimens for immunohistochemical staining
For immunohistochemical staining, the tumor was resected and fixed in a 30% formalin solution at 24 hours after hyperthermia treatment. The tumor tissues were sectioned longitudinally at a 6 -m thickness. These sections were deparaffinized and incubated with 10% skim milk at 378C for 10 minutes to block background staining. They were then incubated at 378C for 60 minutes with mouse anti -rat IgG to TNF -antibody ( Santa Cruz Biotechnology, Santa Cruz, CA ) and at 378C for 60 minutes with biotinylated goat antimouse IgG. They were subsequently incubated at 378C for 30 minutes with peroxidase -conjugated streptavidin ( DAKO, Kyoto, Japan ). Each step was followed by washing with phosphate buffer (50 mM, pH 7.4 ). Peroxidase activity was visualized by treatment at room temperature for 10 minutes with 0.02% diaminobenzidine tetrahydrochloride solution containing 0.005% hydrogen peroxide. These sections were also stained with hematoxylin and eosin.
Statistical analysis
Levels of statistical significance in the gene expression and tumor growth experiments were evaluated using the MannWhitney rank sum test.
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RESULTS
MCL -induced hyperthermia
One day after MCL injection into the tumor, an AMF was applied to the whole body of the mouse. Figure 1 shows the temperature of the tumor tissue and in the rectum during irradiation with the AMF. Tumor temperature increased rapidly to 468C in 3 minutes and was then maintained for 30 minutes by control of the power of the AMF. When the AMF was turned off, tumor temperature decreased to 368C within 10 minutes. In contrast, the temperature in the rectum did not increase over 388C during the irradiation. This suggests that the MCLs injected into the tumor were heated specifically by the AMF, and that heat generation was controllable by adjusting the power of the AMF generator.
TNF -gene expression in tumors
Both pGadTNF and MCLs were injected into tumors, and the concentration of human TNF -transcript was measured in tumor homogenates following hyperthermia treatment ( Fig 2) . TNF -gene expression driven by the gadd 153 promoter was significantly induced by hyperthermia ( P <.005 ): a 3-fold increase in expression was observed in heated tumors compared to nonheated tumors. Without hyperthermia, the TNF -concentration was 10 -15 pg /mg total protein in the tumor homogenates. However, in hyperthermia -treated tumors, which were heated as shown in Figure 1 , TNF -concentration increased up to 45 pg /mg protein on day 1 (one day after hyperthermia treatment ). The induction of TNF -gene expression peaked on day 1 and gradually decreased until day 5. TNF -was not detectable in mouse serum sampled one day after treatment or in homogenates of tumors from control animals ( hyperthermia alone or no treatment).
Therapeutic effect of MCL -induced hyperthermia combined with TNF -gene therapy driven by the gadd 153 promoter
Tumor growth after pGadTNF transfection is shown in Figure 3 . A control group of five mice was injected with empty liposomes and MCLs, but AMF was not applied. Tumor volume increased over 30 days in the control group and the average tumor volume on day 32 was 6.6 ± 2.2 cm 3 . In the case of the gene therapy group, which was injected with pGadTNF -containing liposomes and MCLs but not irradiated, tumor volume was significantly suppressed from day 17 after treatment as compared with the control group ( P <.05). Average tumor volume on day 32 was 2.9 ± 1.1 cm 3 ( P <.01). For the hyperthermia group, both empty liposomes and MCLs were injected and AMF was applied. The time course of tumor volume was similar to that observed for the gene therapy group. Tumor temperature increased up to 468C, as shown in Figure 1 . Tumor volume was significantly suppressed from day 14 after the treatment ( P <.05 ) and was 2.0 ± 1.1 cm 3 on day 32 ( P< .005 ). For the combined therapy group, tumor volumes decreased slightly until day 5, were suppressed from day 8 (P < .05), and then were strongly arrested for 30 days and the average tumor volume on day 32 was 0.5 ± 0.4 cm 3 (P < .005 ), which was significantly smaller than that of the hyperthermia (P <.01) or TNF -gene treatments ( P <.005 ).
Histological study
Histological observation showed that in tumors injected with empty liposomes and MCLs without hyperthermia treatment, the MCLs injected into the center of tumor remained in the tumor owing to their positive charges (Fig 4A ) . However, in the tumors injected with pGadTNF -containing liposomes and MCLs and irradiated, the MCLs spread throughout the Figure 2 . Induction of TNF -gene expression driven by the gadd 153 promoter. Tumors were transfected with pGadTNF and treated with ( ) or without ( 6 ) hyperthermia using MCLs. TNF -gene expression was determined in tumor homogenates from animals sacrificed at indicated times after hyperthermia treatment using the human TNF --specific ELISA that does not detect murine TNF -. TNF -concentration ( pg / mg protein ) represents picogram TNF -/ milligram of total protein in the tumor homogenates. Each point represents the means ± SD of five mice. In nontransfected tumors with and without hyperthermia, no human TNF -was detectable. *P < .05; **P < .01; ***P < .005. ITO, SHINKAI, HONDA, ET AL: HEAT-INDUCIBLE TNF-GENE THERAPY tumor and a large necrotic area was also observed as a result of hyperthermia ( Fig 4B ) . The area of necrotic cell death was about 80% of the area of the tumor affected by hyperthermia. Immunohistochemical observation revealed that the cells in peripheral areas of the tumor survived hyperthermia and expressed TNF -strongly (Fig 4D ) . TNF -was not observed in tumors that had not been transfected with pGadTNF, whether they were irradiated ( data not shown ) or untreated (Fig 4C ) .
DISCUSSION
We have demonstrated the feasibility of a combined TNFgene therapy and hyperthermia strategy. TNF -has a growth inhibition effect on some human glioma cells, although other glioma cells are resistant. We previously demonstrated that U251 -SP cells showed a resistance to TNF -in vitro. 19 However, when pGadTNF transfection was combined with hyperthermia, a synergistic cell killing effect was observed. In the present in vivo study, TNFexpression alone was not able to promote strong tumor growth arrest (Fig 3) . However, when the transfected tumors were heated, TNF -gene expression was induced ( Fig 2 ) and a synergistic effect of TNF -and hyperthermia was observed (Fig 3) . These results suggest that the combination therapy can arrest tumor growth strongly compared with hyperthermia or TNF -gene therapy alone.
Although the MCLs could induce cell death throughout most of a treated tumor by heating under AMF (Fig 4B ) , tumors did not decrease in size (Fig 3 ) . However, the heat stress increased TNF -gene expression from the gadd 153 promoter even at the periphery of the tumor, enhancing the therapeutic effect. This TNF -gene expression area coincided with the area where the hyperthermic effect was not enough to cause cell death. The combined therapy promoted cell killing throughout the tumor and effectively arrested tumor growth over 30 days as shown in Figure 3 . TNF -gene expression in the peripheral area can be important for the treatment of malignant glioma characterized by neovascular formation, because TNF -damages the tumor vasculature.
In TNF -gene therapy, several groups have reported that intratumorally injected adenovirus can leak into systemic circulation and induce abnormally high levels of cytokines, which leads to serious side effects. 23, 24 Therefore, TNFgene therapy in practice is also limited by systemic toxicity in some cases. One of the typical side effects of TNF -is Figure 3 . U251 -SP tumor volumes in athymic mice treated with pGadTNF and hyperthermia using MCLs. 6; Control group: tumors were injected with empty liposomes in PBS on day 0 and with MCLs on day 1, AMF was not applied.~; Gene therapy group: tumors were transfected with pGadTNF on day 0 and injected with MCLs on day 1, but without an AMF irradiation. &; Hyperthermia group: tumors were injected with empty liposomes in PBS on day 0 and with MCLs on day 1 and an AMF was applied on day 2. ; Combined therapy group: tumors were transfected with pGadTNF on day 0 and injected with MCLs on day 1 and an AMF was applied on day 2. Five mice in each group were used for monitoring tumor growth. The experiment was performed at least twice. Inset figures represent a smaller scale used in the first few days after treatment. *P < .05; **P < .01; ***P < .005. hepatocellular degeneration. In the present study, however, no TNF -was detectable in the systemic circulation. This means that there is no measurable systemic release of the cytokine, thus limiting the side effect of TNF -. Moreover, no liver damage was detected in any of the mice on day 32 after transfection with pGadTNF (data not shown ). Mizuno et al 25 reported that conjugation of antibody to cationic liposomes enhanced gene expression in targeted cells. In the present study, we have used MCLs that are designed for direct injection into tumors, but we have already succeeded in the preparation of an antibody -conjugated magnetoliposome for more specific targeting and demonstrated its accumulation in tumors in vivo. 26 In either case, magnetites are heated only under AMF irradiation. Therefore, even though MCLs can leak into systemic circulation, heat is only generated where the AMF is applied. In our strategy, therapeutic gene expression only occurs where the AMF is applied.
This combined treatment arrested tumor growth strongly over 30 days and there was no measurable systemic release of TNF -. We conclude that a powerful and safe treatment for tumors is possible using this novel strategy.
